Frazier Life Sciences
Investor profile
Venture capital
Frazier Life Sciences has backed 2 European tech companies across 2 funding rounds between 2022 and 2025, joining rounds totalling €435M. Most active in Healthtech. Data as of Nov 2026.
Deals
2
distinct rounds
Companies
2
backed
Active span
2022–2025
4 yrs
Total round €
€435M
sum of rounds joined
Deals by year
distinct rounds / yearFrazier Life Sciences — deals by year — interactive chart.
Data table
| Frazier Life Sciences — deals by year | |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
Top sectors
by dealsFrazier Life Sciences — top sectors — interactive chart.
Data table
| Frazier Life Sciences — top sectors | |
|---|---|
| Healthtech | 2 |
Stages
by dealsFrazier Life Sciences — stages — interactive chart.
Data table
| Frazier Life Sciences — stages | |
|---|---|
| Other | 1 |
| Series C | 1 |
Countries
by dealsFrazier Life Sciences — countries — interactive chart.
Data table
| Frazier Life Sciences — countries | |
|---|---|
| Germany | 1 |
| Switzerland | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Venrock Healthcare Capital Partners2
- Andera Partners1
- Ascenta Capital1
- Bayern Kapital1
- Cowen Healthcare Investments1
- Deep Track Capital1
- Driehaus Capital Management1
- EQT Life Sciences1
- Eventide Asset Management1
- Forbion's Growth Opportunities Fund1
- FundPlus1
- High-Tech Gründerfonds (HTGF)1
- Marshall Wace1
- Nextech Invest1
- OCCIDENT1
- OrbiMed1
- Seventure Partners1
- Surveyor Capital1
- TCG X1
- Vivo Capital1
- Wellington Partners1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Tubulis Technologies | Germany | 1 | €308M |
| Vectivbio | Switzerland | 1 | €127M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Tubulis Technologies | Series C | €308M | 2025-10 |
| Vectivbio | Other | €127M | 2022-10 |